Brooks Laboratories is currently trading at Rs. 105.05, up by 5.00 points or 5.00% from its previous closing of Rs. 100.05 on the BSE.
The scrip opened at Rs. 105.05 and has touched a high and low of Rs. 105.05 and Rs. 105.05 respectively. So far 8223 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 155.00 on 16-Sep-2021 and a 52 week low of Rs. 70.00 on 12-May-2022.
Last one week high and low of the scrip stood at Rs. 105.05 and Rs. 82.70 respectively. The current market cap of the company is Rs. 247.15 crore.
The promoters holding in the company stood at 66.41%, while Non-Institutions held 33.59% stake in the company.
Brooks Laboratories’ subsidiary company -- Brooks Steriscience (BSL) has received approval for Meropenem Injection 500mg per vial and 1gram per vial (the product) from the United States Food & Drug Administration (USFDA). The product is generic equivalent to the Merrem Injection of Pfizer Inc.
This approval from USFDA marks Brooks’ foray into the US, which is the largest generic market in the World. Brooks manufactures its carbapenem range of injectables at its dedicated facility at Vadodara, India. The facility is approved by several regulatory agencies, including the European Union, and is equipped to produce a wide range of products meeting global quality standards.
Meropenem Injection is an intravenous beta-lactam antibiotic used to treat various bacterial infections. It is indicated for treating complicated skin and skin structure infections, intra-abdominal infections, and bacterial meningitis to reduce the development of drug-resistant bacteria and maintain the effectiveness of the injection and other antibacterial drugs. Meropenem has an estimated market size of $78 million for the twelve months ending June 2022. In May 2022, BSL also received the marketing authorization for Meropenem injections in the United Kingdom and European Union. Global Penem market is $2.6 billion as on June 2022.
Brooks Laboratories is a pharmaceutical contract research and manufacturing services company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
